XML 30 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
Divestiture of Businesses
 12 Months Ended
Mar. 31, 2017
Discontinued Operation, Income (Loss) from Discontinued Operation Disclosures [Abstract]  
Divestiture of Businesses
Discontinued Operations
Brazil Distribution Business
During the fourth quarter of 2015, we committed to a plan to sell our Brazilian pharmaceutical distribution business, which we acquired through our February 2014 acquisition of Celesio, from our Distribution Solutions segment. Accordingly, the results of operations and cash flows of this business were classified as discontinued operations for all periods presented in our consolidated financial statements. We recorded pre-tax non-cash impairment charges of $241 million ($235 million after-tax) to reduce the carrying value of this Brazilian distribution business to its estimated fair value, less costs to sell, based on our assessment at that time.
On May 31, 2016, we completed the sale of our Brazilian pharmaceutical distribution business and recognized an after-tax loss of $113 million within discontinued operations in the first quarter of 2017 primarily for the settlement of certain indemnification matters as well as the release of the cumulative translation losses. We made a payment of approximately $100 million related to the sale of this business.

Technology Solutions Businesses

During the first quarter of 2015, we decided to retain the workforce business within our International Technology business. This business consists of workforce management solutions for the National Health Service in the United Kingdom. We reclassified the workforce business, which had been designated as a discontinued operation since the first quarter of 2014, to continuing operations in the first quarter of 2015. As a result, during the first quarter of 2015, we recorded non-cash pre-tax charges of $34 million ($27 million after-tax) primarily associated with depreciation and amortization expense for 2014 when the business was classified as held for sale. The non-cash charge was recorded in our consolidated statement of operations primarily in cost of sales.
During the second quarter of 2015, we completed the sale of a software business within our International Technology business and recorded a pre-tax and after-tax loss of $6 million.
A summary of results of discontinued operations is as follows:
 
Years Ended March 31,
(In millions)
2017
 
2016
 
2015
Revenues
$
—

 
$
1,603

 
$
2,196

 
 
 
 
 
 
Loss from discontinued operations
$
(10
)
 
$
(24
)
 
$
(321
)
Loss on sale
(113
)
 
—

 
(6
)
Loss from discontinued operations before income tax
(123
)
 
(24
)
 
(327
)
Income tax (expense) benefit
(1
)
 
(8
)
 
28

Loss from discontinued operations, net of tax
$
(124
)
 
$
(32
)
 
$
(299
)

As of March 31, 2017 and 2016, the carrying amounts of total assets and liabilities of discontinued operations were $24 million and $43 million and $635 million and $660 million.
Divestiture of Businesses
During the second quarter of 2016, we sold our ZEE Medical business within our Distribution Solutions segment for total proceeds of $134 million and recorded a pre-tax gain of $52 million ($29 million after-tax) from this sale.

During the first quarter of 2016, we also sold our nurse triage business within our Technology Solutions segment for net sale proceeds of $84 million and recorded a pre-tax gain of $51 million ($38 million after-tax) from the sale.

These divestitures did not meet the criteria to be reported as discontinued operations since they did not constitute a significant strategic business shift.  Accordingly, pre-tax gains from both divestitures were recorded in operating expenses within continuing operations of our consolidated statements of operations. Pre- and after-tax income of these businesses were not material for the year ended March 31, 2016.